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由于缺乏有效的 HEV 细胞培养模型，对 HEV 的病毒颗粒组装、感染机制






p239 的基础上，利用原核表达系统开展 p495 蛋白的表达、体外组装、免疫原性
和假病毒包装等研究，以期为戊型肝炎病毒的研究提供新的工具。 
首先，本研究利用大肠杆菌表达系统可溶性表达 p495 蛋白，并通过突
变分析发现，Leu244 为 p495 蛋白可溶性表达的关键位点。采用阴离子交换层
析等方法获得纯度约 90%的 p495 蛋白，通过摸索蛋白颗粒组装的条件，包
括组装时溶液的 pH、盐离子浓度和温度等，确定 20-50mM PB6.5、0.5M NaCl、
37℃是 p495 的颗粒体外组装的较优条件，并发现 Pro284 为 p495 蛋白组装的
关键位点之一。 
其次，透射电镜观察和动态光散射测定显示，p495 可形成为形态均一、半
径为 15nm 左右的 VLP；免疫反应性分析表明，p495 与各种 HEV 特异单抗反应
性良好，与 p239 的反应性相当；p495 在小鼠体内的半数有效剂量（ED50）为
0.068μg，0.5μg 剂量可诱导的小鼠抗体水平为 105，与已上市的 p239 疫苗 Hecolin®
免疫原性相当。 















够表达 GFP 的质粒载体与其进行共组装，采用 HPLC 分子筛的双波长紫外检测
和组装颗粒的细胞感染实验，提示 p495 可包裹质粒 DNA，并在细胞内表达 GFP
报告基因，显示了用于制备 HEV 假病毒的可行性。 
综上所述，本研究首次利用大肠杆菌可溶性表达了 HEV p495 蛋白，其中的
Leu244 和 Pro284 分别在可溶性表达和颗粒组装中起重要的作用，组装获得形
态均一的病毒样颗粒，具有良好的免疫反应性和免疫原性，这些颗粒可感染





















Hepatitis E virus (HEV) is a non-enveloped RNA virus and can cause an acute 
viral hepatitis with the symptoms of inappetence, nausea and vomit. It also can cause 
liver failure and is responsible for unusually high rates of mortality in pregnant 
women, patients with chronic liver disease, the aged and infants. HE has been paid 
more attention as it is a pathogen which is hazardous to health. 
Since there is no efficient cell culture model of HEV, HEV VLP assembly, 
infection mechanism and vaccine development are researched through various 
heterologous expression systems. Previous study has shown that HEV ORF2 
aa112-606 (p495) is able to assemble into virus-like particles in insect cells, but there 
is no report about p495 assembly in vitro and expression in E coli. Pseudovirus which 
is infectious and invade the cell can be prepared following with the packaging of 
nucleic acid in vitro, thus it can be used on research of interaction between virus and 
host cell, mechanism for entry cell, virus receptors and evaluation of vaccine efficacy. 
We researched the expression of p495 in E coli system, assembly in vitro, 
immunogenicity and its pseudovirus based on p239 (which is the first recombinant 
HEV vaccine prepared by our research group), and we hope that it can be a new tool 
for the research of HEV. 
First, we expressed p495 from bacterially expressed soluble precursor, and found 
the amino acids, Leu244, is important to soluble expression of p495. Then p495 protein 
with purity of 90% are acquired by purification with anion chromatography. After that, 
we established an efficient self-assembly method which showed 20-50mM PB6.5, 
0.5M NaCl and 37℃is the most suitable for formation of p495 VLPs by researching 
its assmbly conditions, such as salt ions concentrations, pH and temperature of 
assembly buffer and found the amino acids, Pro284, played an important role in the 
process of assembly of p495. 
Secondly, Transmission Electron Microscopy (TEM) and Dynamic Light 















homogeneous and radius of 15nm). The immunoreactivity of p495 is well with HEV 
monoclonal antibodies and is same as p239. After immunization, the ED50 of p495 is 
0.068μg, also they can elicit higher titers of HEV antibodies (which is the same as 
Hecolin®) in mouse at 0.5μg dose.  
Thirdly, p495 also have the ability of cellular attachment (we used HepG2 cell 
line) , and we prepared HEV pseudovirus through adding exogenous gene (such as 
GFP recombinant plasmid) to p495 in the self-assembly process. We confirmed 
feasibility of preparation of HEV pseudovirus through dual-wavelength ultraviolet 
HPLC analysis and cell infection. 
In a conclusion, we firstly generated HEV p495 from bacterially expressed 
soluble precursor and found the important amino acids Leu244 and Pro284 for sucessful 
soluble expression and self-assembly in vitro respectively. These VLPs are  
homogeneous and have good immunoreactivity and immunogenicity, they also have 
the ability of cellular attachment and packaging of DNA in vitro. Therefore, our 
findings lay the foundation of research of mechanism for HEV capsid assembly and 
cell infection and identification of receptors, and it also significantly provide guidance 
for design of HEV vaccine based on E coli. The application of pseudovirus will 
advance the development of HEV cell and animal models. 
Key words: Hepatitis E virus; E coli expression system; virus like particles; 


















Amp: Ampicillin, 氨苄青霉素 
AUC: Analytical Ultracentrifugation, 分析型超速离心 
Bp: base pair, 碱基对 
NV: Norwalk Virus,诺瓦克病毒 
DLS: Dynamic Light Scattering, 动态光散射 
DNA: Deoxyribonucleic Acid, 脱氧核糖核酸 
ELISA: Enzyme-linked ImmunoSorbant Assay, 酶联免疫吸附测定 
GAM-AP: 标记碱性磷酸酶的羊抗鼠抗体 
GAM-HRP: 标记辣根过氧化物酶的羊抗鼠抗体 
GFP: Green Fluorescent Protein, 绿色荧光蛋白 
HPLC: High Performance Liquid Chromatography, 高效液相色谱 
HEV: Hepatitis E virus, 戊型肝炎病毒 
HRP: Horseradish Peroxidase, 辣根过氧化物酶 
Kan: Kanamycin, 卡那霉素 
KDa: kilo Daltons, 千道尔顿 
Mab: monoclonal antibody, 单克隆抗体 
ORF: Open Reading Frame, 开放阅读框 
RNA：Ribonucleic Acid, 核糖核酸 
mRNA：Messenger RNA，信使 RNA 
DEAE FF: DEAE SepharoseTM Fast Flow, 阴离子交换层析介质 
SV: Sedimentation Velocity, 沉降速度 
TEM: Transmission Electron Microscopy, 透射电子显微镜 
VLPs: Virus-Like Particle(s), 病毒样颗粒 
pH: hydrogen ion concentration, 氢离子浓度指数 
IEM : immuno-electron microscopy, 免疫电镜 
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1.1 天然 HEV 的结构 
天然 HEV 为球状颗粒，直径约 27-34nm。1983 年，Balayan 等首次利用免
疫电镜（immuno-electron microscopy，IEM）观察到戊肝病毒（如图 1），天然
HEV 有实心和空心两种颗粒[7]。进一步研究发现 HEV 为表面有裂痕的 T=3 的二





  图 1 利用免疫电镜观察 HEV 天然病毒颗粒 
  Fig.1 Native HEV particles visualized by IEM 
 (quoted from Centers for Disease Control and Prevention(CDC), Atlanta, USA) 
 
1.2 HEV 基因组及编码蛋白的研究 
















离株[11-13]，Tam 等于 1991 年首次报道其全基因序列（如图 2）。其基因组包含 3 
个开放性读码框（ORF），并且有 3’端长 poly（A）尾巴结构和 5’端含帽结
构。 
ORF1 位于基因组 5’端。其编码的肽段序列上含有一个甲基转移酶、蛋白




  图 2 戊型肝炎病毒的基因组组织结构 
  Fig.2 Genomic organization of HEV 





























明ORF2 编码的蛋白存在着重要的中和表位[22-24] 。现有研究结果表明HEV 的主
要中和表位区域集中于ORF2 所编码蛋白的aa459～606 之间，并且也是主要介
导HEV与嗜性细胞吸附的区域[25, 26] 。 
 
 
   
图3 HEV基因1的PORF2蛋白结构图[27, 28] 
Fig.3 The structure of genotype-1 pORF2 protein 
(A) Ribbon representations of S, M, and P. The structure is covered from blue (N 
terminus of the domain) to red (C terminus of the domain). (B)  Dimer 
structure of the capsid protein. One subunit is colored red, and the other subunit 
is colored according to its domain structure (blue, S domain; green, M domain; 
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